Ultrasound Genetic Medicine Platform Advances Toward Clinic
SonoThera closed an oversubscribed $125M Series B financing to advance DMD and ADPKD programs toward the clinic, validating its non-viral genetic medicine delivery platform.
All categories
GSK Acquires Nuvalent for $10.6B
GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild…
Parabilis IPO Expansion
Parabilis, formerly FogPharma, increased its planned IPO size to as much as $636.8 million, potentially becoming one of the largest biotech IPOs in recent years. The financing represents a major validation event for the…
Incyte Acquires Vega Therapeutics
Incyte agreed to acquire Vega Therapeutics for up to $2.0 billion, adding Phase 3 asset VGA039, a first-in-class Protein S-modulating antibody for von Willebrand disease. The deal represents Incyte’s most significant strategic move beyond…
Nurix + Roche; Global BTK Degrader Collaboration
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
AbbVie – EHA 2026 Hematology Portfolio Update
AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a…
Lilly + Ascidian – $1.9B RNA Exon Editing Deal
Eli Lilly signed a collaboration with Ascidian worth up to $1.9B to develop in vivo RNA exon-editing therapies for inherited kidney diseases, validating RNA exon editing as a major emerging genetic medicine modality.
Karyopharm – SENTRY Phase 3 Full Data in Frontline Myelofibrosis
Karyopharm delivered one of the most important myelofibrosis datasets of 2026. In the Phase 3 SENTRY study, selinexor plus ruxolitinib nearly doubled spleen response rates versus ruxolitinib alone (49.8% vs 28.0%) and generated an…
Kelonia Therapeutics – In Vivo CAR-T Clinical Update
Kelonia Therapeutics presented updated ASCO 2026 data supporting continued advancement of its in vivo CAR-T platform, which engineers CAR-T cells directly inside patients using targeted lentiviral delivery technology.
TUNE-401 Epigenetic Silencing Clinical PoC
Tune Therapeutics presented the first clinical proof-of-concept data for CRISPR-based epigenetic silencing in humans, demonstrating deep, dose-dependent and durable reductions in HBV biomarkers with TUNE-401 in chronic hepatitis B patients.
